# Efficacy of Romiplostim in Treatment of SAA in Adults Previously Untreated With or Refractory to Immunosuppressive Therapy

> **NCT05323617** · PHASE2 · WITHDRAWN · sponsor: **Amgen**

## Conditions studied

- Severe Aplastic Anemia (SAA)

## Interventions

- **DRUG:** Romiplostim
- **DRUG:** Antithymocyte Globulin
- **DRUG:** Cyclosporine A

## Key facts

- **NCT ID:** NCT05323617
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-08-31
- **Primary completion:** 2025-02-25
- **Final completion:** 2025-02-25
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Operational
- **Last updated:** 2023-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05323617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05323617, "Efficacy of Romiplostim in Treatment of SAA in Adults Previously Untreated With or Refractory to Immunosuppressive Therapy". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT05323617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*